PMID- 27144279
OWN - NLM
STAT- MEDLINE
DCOM- 20170208
LR  - 20181202
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 61
IP  - 6
DP  - 2016
TI  - Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia.
PG  - 323-30
LID - 10.1159/000445425 [doi]
AB  - BACKGROUND: Tigecycline is an antibiotic agent with a broad spectrum, which has 
      an antibacterial effect against many multidrug-resistant organisms. However, its 
      clinical efficacy in the treatment of hospital-acquired pneumonia (HAP) is 
      disputed. MATERIALS AND METHODS: In this report, a systematic review and 
      meta-analysis were conducted to evaluate the efficacy and safety of tigecycline 
      for the treatment of HAP. The primary outcome was the rate of clinical cure, and 
      the secondary outcomes were mortality and adverse events (AEs). RESULTS: Four 
      trials involving 1,234 patients were included. The standard-dose tigecycline and 
      comparator groups did not differ significantly in their rates of clinical cure. 
      However, high-dose tigecycline was more effective than standard-dose tigecycline 
      or the comparators for the treatment of HAP. There was no significant difference 
      in mortality between the standard-dose or high-dose regimen and the comparators. 
      Although the safety profile of standard-dose tigecycline was similar to the 
      comparators, the high-dose regimen exhibited more AEs compared with the other 
      groups. CONCLUSION: High-dose tigecycline is efficient for the treatment of HAP 
      but is associated with more AEs.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Xu, Li
AU  - Xu L
FAU - Wang, Ya-Li
AU  - Wang YL
FAU - Du, Shuai
AU  - Du S
FAU - Chen, Lin
AU  - Chen L
FAU - Long, Li-Hui
AU  - Long LH
FAU - Wu, Yan
AU  - Wu Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160504
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Anti-Bacterial Agents)
RN  - 70JE2N95KR (Tigecycline)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - Anti-Bacterial Agents/adverse effects/pharmacokinetics/*therapeutic use
MH  - Databases, Factual
MH  - Female
MH  - Half-Life
MH  - Hospitals
MH  - Humans
MH  - Male
MH  - Minocycline/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic 
      use
MH  - Odds Ratio
MH  - Pneumonia/*drug therapy/mortality/pathology
MH  - Tigecycline
EDAT- 2016/05/06 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/05/05 06:00
PHST- 2015/09/28 00:00 [received]
PHST- 2016/03/12 00:00 [accepted]
PHST- 2016/05/05 06:00 [entrez]
PHST- 2016/05/06 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - 000445425 [pii]
AID - 10.1159/000445425 [doi]
PST - ppublish
SO  - Chemotherapy. 2016;61(6):323-30. doi: 10.1159/000445425. Epub 2016 May 4.